Halozyme Therapeutics (NASDAQ:HALO) Releases Earnings Results, Beats Estimates By $0.02 EPS

Halozyme Therapeutics (NASDAQ:HALO) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02, Zacks reports. The firm had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 165.13%.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $57.29 on Thursday. The company has a market cap of $7.29 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The firm has a fifty day moving average of $53.07 and a 200-day moving average of $54.56. Halozyme Therapeutics has a 1 year low of $36.61 and a 1 year high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HALO. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.